At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the recent progress in understanding clinically relevant genomic alterations in kidney cancer. Genomic profiling of collecting duct carcinomas, a rare kidney cancer subtype, revealed a high frequency of NF2 genomic alterations, which may represent opportunities for the application of targeted therapies.
Molecular characterisation of kidney cancer and opportunities for targeted therapies
10th July 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?